A modified PF4-dependent, CD62p expression assay selectively detects serotonin-releasing antibodies in patients suspected of HIT

Anand Padmanabhan; Curtis G. Jones; Daniel W. Bougie; Brian R. Curtis; Janice G. McFarland; Demin Wang; Richard H. Aster

doi:10.1160/TH15-02-0175

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2015; 114(06): 1322-1323
DOI: 10.1160/TH15-02-0175

Letter to the Editor

Schattauer GmbH

A modified PF4-dependent, CD62p expression assay selectively detects serotonin-releasing antibodies in patients suspected of HIT

Authors

Anand Padmanabhan

¹Medical Sciences Institute, BloodCenter of Wisconsin, Milwaukee, Wisconsin, USA

²Blood Research Institute, Blood-Center of Wisconsin, Milwaukee, Wisconsin, USA

³Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Curtis G. Jones

¹Medical Sciences Institute, BloodCenter of Wisconsin, Milwaukee, Wisconsin, USA
Daniel W. Bougie

²Blood Research Institute, Blood-Center of Wisconsin, Milwaukee, Wisconsin, USA
Brian R. Curtis

²Blood Research Institute, Blood-Center of Wisconsin, Milwaukee, Wisconsin, USA

⁴Platelet and Neutrophil Immunology Laboratory, BloodCenter of Wisconsin, Milwaukee, Wisconsin, USA
Janice G. McFarland

⁴Platelet and Neutrophil Immunology Laboratory, BloodCenter of Wisconsin, Milwaukee, Wisconsin, USA

⁵Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Demin Wang

²Blood Research Institute, Blood-Center of Wisconsin, Milwaukee, Wisconsin, USA

⁶Department of Microbiology & Molecular Genetics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Richard H. Aster

²Blood Research Institute, Blood-Center of Wisconsin, Milwaukee, Wisconsin, USA

⁵Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA

Abstract

Full Text

References

References
1 Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 2009; 135: 1651-1664.
2 Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. Am J Hematol 2007; 82: 1037-1043.
3 Warkentin TE, Levine MN, Hirsh J. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
4 Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program 2011; 2011: 143-149.
5 Morel-Kopp MC, Tan CW, Brighton TA. et al. Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study. Thromb Haemost 2012; 107: 575-583.
6 Padmanabhan A, Jones CG, Bougie DW. et al. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. Blood 2015; 125: 155-161.
7 Hicks LK, Bering H, Carson KR. et al. Five hematologic tests and treatments to question. Blood 2014; 124: 3524-3528.
8 Jy W, Mao WW, Horstman LL. et al. A flow cyto-metric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost 1999; 82: 1255-1259.
9 Vitale M, Tazzari P, Ricci F. et al. Comparison between different laboratory tests for the detection and prevention of heparin-induced thrombocytopenia. Cytometry 2001; 46: 290-295.
10 Cuker A, Arepally G, Crowther MA. et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 2010; 08: 2642-2650.